Research programme: Dual IRAK1/4 and panFLT3 inhibitors - Kurome Therapeutics
Latest Information Update: 28 May 2024
At a glance
- Originator Cincinnati Children's Hospital Medical Center; National Center for Advancing Translational Sciences
- Developer Cincinnati Children's Hospital Medical Center; Kurome Therapeutics
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 Oct 2023 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in USA
- 24 Aug 2023 Kurome Therapeutics plans a phase I trial for Acute myeloid leukemia and Myelodysplastic syndrome in first quarter of 2024 (Kurome Therapeutics pipeline, August 2023)